Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cap. goods stocks lead among losers
Mon, 30 Sep 01:30 pm

Backed by persistent selling activity Indian markets have continued their slide during the post noon trading session. Barring stocks from IT sector, all the sectoral indices are trading in negative territory. Capital goods and metal sector stocks are the leading underperformers.

BSE-Sensex is down by 287 points and NSE-Nifty is trading down by 82 points. While BSE Mid Cap is trading down by 0.72%, BSE Small Cap index is trading down by 0.71%. The rupee is trading at 62.85 to the US dollar.

Most of the Indian pharma stocks are trading in red with Wockhardt Ltd and Panacea biotech leading the pack of losers. Glenmark Ltd, announced that the company has received approval for Hydrocortisone Butyrate Cream USP, 0.1%, drug from the United States Food and Drug Administration (USFDA). The said drug is a generic version of Locoid Lipocream. Glenmark is first to file for this product and hence holds 180-days exclusivity. In April 2011, Glenmark had entered into settlement with the innovator Astellas. As per the agreement, company can launch the drug in CY 2013. The branded market size of the drug is $ 34 m in US and is indicated for the treatment of mild to moderate atopic dermatitis in patients ageing 3 months to 18 years. Glenmark's current portfolio consists of 90 products authorized for distribution in the U.S. market and 53 ANDA's pending approval with the USFDA. Glenmark has a good portfolio of derma products in the US market and this product will further strengthen its product basket. Glenmark was trading up by 1.5% at the time of writing.

Majority of the private banks are trading in the red with Yes bank and Federal bank being the major losers. Only ING Vysya bank and J&K bank are trading in the green. As per a leading financial daily, Yes Bank is increasing focus on emerging sectors such as life sciences, IT, education and healthcare to tide over the tough macro-economic environment. As per the bank, these sectors are largely driven by domestic consumption particularly in the under-penetrated markets in rural regions. Therefore, the bank sees tremendous scope to partner companies operating in these sectors. Yes Bank, in its road-map, has said that it will quadruple its size over the next five years and has said that it is on track in terms of growth strategy which it chartered out three and half years ago. For the quarter ended June 2013, the bank's net interest income grew by 40% YoY on the back of 29% YoY growth in advances. Its bottomline grew by 38% YoY despite higher provisioning. The net interest margin improved to 3% from 2.8% in 1QFY13, due to rise in proportion of CASA deposits.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Cap. goods stocks lead among losers". Click here!


Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Feb 26, 2021 (Close)